Research N Reports

Nuclear Medicine Market to Grow at a Healthy CAGR of 8.1% by 2025 According to New Research

Research N Reports has added a new research report, titled "Nuclear Medicine Market by Product (Diagnostic Medicine [SPECT Radiopharmaceuticals and PET Radiopharmaceuticals] and Therapeutic Medicine [Beta Emitters, Alpha Emitters and Brachytherapy Isotopes]); by Application (Bone Metastasis, Cardiology, Endocrine Tumors, Lymphoma, Neurology, Oncology, Thyroid and Others); by Regions (North America, Asia Pacific, Europe, the Middle East & Africa and Latin America) – Global Insights Growth, Size, Comparative Analysis, Trends and Forecast, 2017-2025."


Houston, TX -- (SBWIRE) -- 01/23/2018 -- Nuclear medicine uses required amounts of radioactive materials, also called as radiotracers that are injected into the bloodstream, inhaled or swallowed. These radiotracers travel through the area which is to be examined and gives off energy in the form of gamma rays. These rays are detected by a special camera and a computer in order to create images of the inside of the body. Nuclear medicine imaging helps generate unique information that often cannot be obtained using any other imaging procedures. It also offers the potential to identify any disease in its earliest stages.

For Sample copy of this report:

It helps detect cancers, heart diseases, neurological disorders, gastrointestinal malfunction, endocrine, and various other abnormalities within the body. As nuclear medicine procedures are capable to pinpoint molecular activity in the body, they offer potential to identify the patient's response to therapeutic interventions. With increase in the number of cancer affected population and adoption of SPECT scans, this market is anticipated to grow during the forecast period. The equipment is expensive and hence can hinder the growth curve of this market. Eventually, high demand for radio isotopes is an opportunity for this market. Global nuclear medicine market is anticipated to rise at a CAGR of 8.1% from 2017 to 2025.

Avail Discount on this report:

Based on product, this market is segmented into diagnostic medicine which is further segmented into SPECT radiopharmaceuticals and PET pharmaceuticals; and therapeutic medicine which is further segmented into beta emitters, alpha emitters and brachytherapy isotopes. Diagnostic medicine only helps in the determination of the disease and a detailed condition of the body is stated. Therapeutic medicine help cure the diseases using radioactive substances in the treatment. Diagnostic medicine accounted for major share of global nuclear medicine market in 2016 and this is expected to increase in the near future. Furthermore, SPECT radiopharmaceuticals accounted as the largest diagnostic medicine segment in 2015.
In terms of application this market is branched into Bone Metastasis, Cardiology, Endocrine Tumors, Lymphoma, Neurology, Oncology, Thyroid and Others. The development of functional brain nuclear medicine techniques and their application in the investigation of neuropsychiatric disorders, have contributed significantly in the illumination of the underlying pathophysiological processes of these disorders. Each and every treatment or diagnosis of the disease is done in most precise stages. Oncology stood as the largest and fastest growing application segment in 2015.

For more information:

Based on region, the global nuclear medicine market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa and Latin America. North America is expected to be the leading market during the forecast period of 2016 to 2021. The rest are anticipated to follow the increasing trend in the coming years.

This report covers a complete analysis of the competitive landscape of the global nuclear medicine market. It includes company profiles of few key market players such as Cardinal Health, Inc, GE Healthcare, Bracco Imaging S.p.A, Nordion, Inc., Bayer HealthCare Medical Care, Lantheus Medical Imaging Inc, Advanced Medical Isotope Corporation, Alliance Medical, Alseres Pharmaceuticals, Inc, Avid Radiopharmaceuticals, Actinium Pharmaceuticals Inc, Ion Beam Applications S.A, Immunomedics, Inc., Jubilant Pharma, Mallinckrodt Pharmaceuticals, Medi-Radiopharma Ltd, Peregrine Pharmaceuticals, Inc., Siemens Healthcare, Positron Corporation and Triad Isotopes, Inc.